Emerging personalized approaches for the management of advanced urothelial carcinoma
نویسندگان
چکیده
منابع مشابه
Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches
The current standard of care for metastatic urothelial carcinoma is cisplatin-based chemotherapy but treatment is generally not curative. Mechanisms of resistance to conventional cytotoxic regimens include tumor cell drug efflux pumps, intracellular anti-oxidants, and enhanced anti-apoptotic signaling. Blockade of signaling pathways with small molecule tyrosine kinase inhibitors has produced dr...
متن کاملAdvanced urothelial carcinoma: moving the field forward.
Advanced urothelial carcinoma (UC) is a devastating illness with limited effective chemotherapy options for patients with metastatic disease. Molecularly targeted therapy has demonstrated substantial activity in many malignancies, including non–small-cell lung cancer (NSCLC), melanoma, breast cancer, colorectal cancer, and others. Over the past several years, the biology of UC has been better d...
متن کاملChemotherapy and Management of Locally Advanced Carcinoma Cervix
Background & Objective:the present study was undertaken to ascertain the incidence of early, advanced cancer cervix and its recurrence and role of chemotherapy in locally advanced cancer cervix. Material and Methods: The present study was conducted in the Departments of Obstetrics & Gynaecology, Pathology and Radiotherapy and the specimens examined in the Department of Pathol...
متن کاملRole of FGFR3 in Urothelial Carcinoma
Background and Objective: This study was undertaken to analyze the immunohistochemical expression of fibroblast growth factor receptor (FGFR3) in urothelial carcinoma and correlate its expression with the pathological stage, recurrence and other clinicopathological parameters. Material and Methods: A retrospective study was undertaken on paraffin blocks o...
متن کاملAccelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
Since the accelerated approval of atezolizumab in May 2016 [1], the U.S. Food and Drug Administration (FDA) has approved four additional programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) targeted immunotherapies for the treatment of patients with locally advanced or metastatic urothelial cancer. This includes the treatment of patients who have received prior platinum-contain...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Anticancer Therapy
سال: 2012
ISSN: 1473-7140,1744-8328
DOI: 10.1586/era.12.141